insurance coverage glp 1 GLP-1 Statistics 2026 | Employer, Medicare & Medicaid Data GLP-1s and The Payer Predicament

spending on prescription drugs in 2025 jumped nearly 13% to $915 billion and is projected to surpass $1 trillion in 2026, according to the report by the American Society of Health-System Pharmacists, or ASHP, released April 30

MOF were defined as hip, vertebral, humerus, or forearm fractures

Clinical trial data for FDA-approved GLP-1 receptor agonists demonstrates: Significant weight reduction: Meaningful mean body weight reduction in trial participants (see FDA-approved labeling for specific approved products) Cardiorenal protection: Reduced risk of major adverse cardiovascular events and kidney disease progression Improved lipid profiles: Decreased triglycerides and increased HDL cholesterol Blood pressure reduction: Modest but clinically significant decreases in systolic blood pressure Reduced inflammation: Decreased inflammatory markers associated with metabolic syndrome Note: Clinical outcomes cited above reflect published trial data for FDA-approved GLP-1 receptor agonists

Reduced Reward Sensitivity: By dampening the brain's response to highly rewarding stimuli, GLP-1 RAs might help individuals feel less driven by immediate gratification, which can be beneficial in managing conditions like depression and substance use disorders

Stacking combining two or more peptides with complementary mechanisms allows researchers to examine synergistic effects on muscle growth and recovery